RCKT – Rocket Pharmaceuticals, Inc.

RCKT — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

20.81

Margin Of Safety %

Put/Call OI Ratio

0.11

EPS Next Q Diff

-0.05

EPS Last/This Y

0.99

EPS This/Next Y

-0.14

Price

2.94

Target Price

9.3

Analyst Recom

2.43

Performance Q

-25.81

Upside

-925.7%

Beta

0.5

Ticker: RCKT

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-23	RCKT	3.69	0.08	0.01	14913
2026-04-24	RCKT	3.53	0.07	0.09	15167
2026-04-27	RCKT	3.48	0.07	0.00	15363
2026-04-28	RCKT	3.44	0.07	0.01	15321
2026-04-29	RCKT	3.48	0.07	0.03	16403
2026-04-30	RCKT	3.49	0.07	0.00	16343
2026-05-01	RCKT	3.56	0.07	0.05	16356
2026-05-04	RCKT	3.61	0.07	0.25	16430
2026-05-05	RCKT	3.54	0.07	0.00	16506
2026-05-06	RCKT	3.86	0.07	0.01	16512
2026-05-07	RCKT	3.72	0.07	0.13	16529
2026-05-08	RCKT	3.63	0.07	0.15	16112
2026-05-11	RCKT	3.6	0.07	0.06	16127
2026-05-12	RCKT	3.64	0.08	0.07	16172
2026-05-13	RCKT	3.59	0.08	0.13	16188
2026-05-14	RCKT	3.39	0.08	0.02	16241
2026-05-15	RCKT	3.26	0.07	0.01	16255
2026-05-18	RCKT	3.08	0.04	0.03	11841
2026-05-19	RCKT	2.91	0.04	0.30	12081
2026-05-20	RCKT	2.96	0.04	4.10	12252
2026-05-21	RCKT	3.1	0.05	6.92	12296
2026-05-22	RCKT	2.94	0.11	0.00	13819
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-23	RCKT	3.68	20.0	-5.8	-1.35
2026-04-24	RCKT	3.53	20.0	9.3	-1.35
2026-04-27	RCKT	3.49	20.0	13.4	-1.35
2026-04-28	RCKT	3.44	20.0	18.4	-1.35
2026-04-30	RCKT	3.49	20.0	14.0	-1.35
2026-05-01	RCKT	3.56	20.0	6.7	-1.35
2026-05-04	RCKT	3.61	20.0	1.2	-1.37
2026-05-05	RCKT	3.53	20.0	9.0	-1.37
2026-05-06	RCKT	3.86	20.0	-33.6	-1.37
2026-05-07	RCKT	3.74	20.0	-12.2	-1.37
2026-05-08	RCKT	3.64	20.0	-1.8	-1.37
2026-05-11	RCKT	3.60	20.0	-	-1.32
2026-05-12	RCKT	3.64	20.0	-	-1.32
2026-05-13	RCKT	3.60	20.0	-	-1.32
2026-05-14	RCKT	3.39	20.0	-	-1.32
2026-05-15	RCKT	3.26	20.0	-	-1.13
2026-05-18	RCKT	3.07	103.1	-	-1.13
2026-05-19	RCKT	2.91	103.1	-	-1.13
2026-05-20	RCKT	2.96	121.6	-	-1.02
2026-05-21	RCKT	3.11	121.6	-	-1.02
2026-05-22	RCKT	2.94	121.6	-	-1.02
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-23	RCKT	-0.50	-4.70	18.13
2026-04-24	RCKT	-0.58	-4.70	18.13
2026-04-27	RCKT	-0.58	-4.82	18.61
2026-04-28	RCKT	-0.58	-4.82	18.61
2026-04-29	RCKT	-0.58	-4.82	18.61
2026-04-30	RCKT	-0.58	-4.82	18.61
2026-05-01	RCKT	-0.58	-4.82	18.61
2026-05-04	RCKT	-0.58	-3.89	18.61
2026-05-05	RCKT	-0.58	-3.89	18.61
2026-05-06	RCKT	-0.58	-3.89	18.61
2026-05-07	RCKT	-0.58	-3.89	18.61
2026-05-08	RCKT	-0.58	-3.89	18.61
2026-05-11	RCKT	-0.58	-3.62	18.60
2026-05-12	RCKT	-0.84	-3.62	21.01
2026-05-13	RCKT	-0.84	-3.62	21.01
2026-05-14	RCKT	-0.84	-3.62	21.01
2026-05-15	RCKT	-0.94	-3.62	21.01
2026-05-18	RCKT	-0.94	-9.43	21.00
2026-05-19	RCKT	-0.95	-9.43	21.14
2026-05-20	RCKT	-0.86	-9.43	21.14
2026-05-21	RCKT	-0.71	-9.43	20.81
2026-05-22	RCKT	-0.96	-9.43	20.81
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.42

Avg. EPS Est. Current Quarter

0.13

Avg. EPS Est. Next Quarter

-0.47

Insider Transactions

-0.96

Institutional Transactions

-9.43

Beta

0.5

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

94.1

Max Drawdown 5-Year %

-95.2

Target Price

9.3

P/E

Forward P/E

PEG

P/S

P/B

1.36

P/Free Cash Flow

EPS

-1.88

Average EPS Est. Cur. Y

-1.02

EPS Next Y. (Est.)

-1.16

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.62

Return on Equity vs Sector %

-115

Return on Equity vs Industry %

-99.4

EPS 1 7Days Diff

0.3

EPS 1 30Days Diff

0.34

EBIT Estimation

◆ RCKT Healthcare

$2.96

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

6/20

Pullback

21/25

Volume

9/15

Valuation

12/20

TP/AR

3/10

Options

8/10

RSI

34.3

Range 1M

7.8%

Sup Dist

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

1/25

Growth

15/30

Estimates

2/20

Inst/Vol

0/15

Options

6/10

EPS Yr

85.6%

EPS NY

-342%

52W%

18%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +214.2% upside

Quality

2/30

Valuation

16/30

Growth

11/25

Stability

8/10

LT Trend

3/5

Upside

+214.2%

Quality

Rocket Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 202

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

RCKT

Latest News

—

Caricamento notizie per RCKT…

stock quote shares RCKT – Rocket Pharmaceuticals, Inc. Stock Price stock today

news today RCKT – Rocket Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RCKT – Rocket Pharmaceuticals, Inc. yahoo finance google finance

stock history RCKT – Rocket Pharmaceuticals, Inc. invest stock market

stock prices RCKT premarket after hours

ticker RCKT fair value insiders trading

RCKT – Rocket Pharmaceuticals, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: RCKT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y